Workflow
20cm速递|科创创新药ETF(589720)午后翻红,“924行情”以来跑赢主要港股创新药指数,近10日净流入超1亿元
Mei Ri Jing Ji Xin Wen·2025-09-12 06:33

Group 1 - The core viewpoint is that China's innovative drugs are entering a stage of realization, with significant R&D progress and resilience against trade frictions, expected to remain a key investment theme in the pharmaceutical sector until 2025 [1] - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies, primarily in high-growth biotech, with a 20% limit on daily price fluctuations to better align with sector volatility [1] - Since the "924 market" period, the Sci-Tech Innovation Drug Index has outperformed major Hong Kong innovative drug indices, with returns from September 24, 2024, to August 29, 2025, showing increases of 122% for the Sci-Tech Innovation Drug Index, 116% for the Hong Kong innovative drug index, and 107% for the Hang Seng Hong Kong Connect innovative drug index [1] Group 2 - The Sci-Tech Innovation Drug Index is expected to provide better participation in the resilience of the Sci-Tech Innovation Board during periods of increased market risk appetite [1]